GlassScriptPhysician profile
Eric James Yoon
NPI 1326046798
$7,137.58
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,513 · 2022: $2,965 · 2023: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,050.73 | 2021-2023 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $1,023.91 | 2021-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $617.10 | 2021-2023 | Evenity, Prolia, Repatha |
| Abbvie INC. | $517.45 | 2021-2023 | |
| Abbott Laboratories | $412.88 | 2021-2023 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.30 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
| Xeris Pharmaceuticals, INC. | $253.86 | 2021-2023 | Gvoke Hypopen |
| Insulet Corporation | $247.66 | 2021-2023 | Omnipod |
| Lilly USA, LLC | $247.44 | 2021-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $239.98 | 2022-2023 | |
| Esperion Therapeutics, INC. | $218.68 | 2021-2023 | Nexletol |
| Antares Pharma, INC. | $213.49 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Amarin Pharma, INC. | $212.58 | 2021-2022 | |
| Zealand Pharma US, INC. | $211.24 | 2021-2022 | |
| Medtronic, INC. | $206.00 | 2022-2023 | Minimed 770g, Minimed 780g |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $160.65 | 2021-2023 | Korlym |
| Merck Sharp & Dohme LLC | $113.25 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $107.09 | 2021-2022 | |
| Clarus Therapeutics INC. | $91.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $66.75 | 2021-2023 | |
| Mannkind Corporation | $62.69 | 2022-2023 | Afrezza |
| Daiichi Sankyo INC. | $62.48 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $59.96 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.20 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.65 | 2021-2023 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $49.83 | 2021-2022 | |
| Pfizer INC. | $43.08 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $40.89 | 2021 | |
| Ucb, INC. | $29.72 | 2021-2022 | |
| Halozyme INC | $22.19 | 2023 | |
| Tolmar, INC. | $15.84 | 2023 | |
| Lifescan, INC. | $13.79 | 2021 | |
| Evoke Pharma, INC. | $12.48 | 2021 | |
| Glaxosmithkline, LLC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.